145 related articles for article (PubMed ID: 11571736)
21. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
Demirag F; Unsal E; Yilmaz A; Caglar A
Chest; 2005 Nov; 128(5):3382-7. PubMed ID: 16304288
[TBL] [Abstract][Full Text] [Related]
23. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
Yan TD; Boyer M; Tin MM; Sim J; Kennedy C; McLean J; Bannon PG; McCaughan BC
Ann Thorac Surg; 2009 May; 87(5):1552-6. PubMed ID: 19379903
[TBL] [Abstract][Full Text] [Related]
24. Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression.
Sivertsen S; Hadar R; Elloul S; Vintman L; Bedrossian C; Reich R; Davidson B
Lung Cancer; 2006 Dec; 54(3):309-17. PubMed ID: 16996643
[TBL] [Abstract][Full Text] [Related]
25. [Clinico-pathological prognostic factors in malignant pleural mesothelioma].
Nakano K; Shiota Y; Ono T; Taniyama K; Hiramoto T; Yamakido M
Nihon Kokyuki Gakkai Zasshi; 2007 Feb; 45(2):153-9. PubMed ID: 17352172
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma.
Ak G; Metintas S; Metintas M; Yildirim H; Erginel S; Kurt E; Alatas F; Cadirci O
J Thorac Oncol; 2009 Nov; 4(11):1425-30. PubMed ID: 19752758
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
28. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
[TBL] [Abstract][Full Text] [Related]
29. Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
31. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.
Strizzi L; Vianale G; Catalano A; Muraro R; Mutti L; Procopio A
Int J Oncol; 2001 May; 18(5):1093-8. PubMed ID: 11295061
[TBL] [Abstract][Full Text] [Related]
32. Adenocarcinoma simulating mesothelioma.
Corrin B; Dewar A
Ultrastruct Pathol; 1996; 20(4):327-9. PubMed ID: 8837338
[TBL] [Abstract][Full Text] [Related]
33. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical differential diagnosis of pleural effusions, with emphasis on malignant mesothelioma.
Wick MR; Moran CA; Mills SE; Suster S
Curr Opin Pulm Med; 2001 Jul; 7(4):187-92. PubMed ID: 11470972
[TBL] [Abstract][Full Text] [Related]
35. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
Hirayama N; Tabata C; Tabata R; Maeda R; Yasumitsu A; Yamada S; Kuribayashi K; Fukuoka K; Nakano T
Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073
[TBL] [Abstract][Full Text] [Related]
36. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
37. Malignant pleural fluid from mesothelioma has potent biological activities.
Cheah HM; Lansley SM; Varano Della Vergiliana JF; Tan AL; Thomas R; Leong SL; Creaney J; Lee YC
Respirology; 2017 Jan; 22(1):192-199. PubMed ID: 27560254
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
O'Kane SL; Cawkwell L; Campbell A; Lind MJ
Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
